Business Context and Reporting Period
This Form 8-K is a current report filed by Biocardia, Inc. on April 20, 2026. The filing discloses a significant regulatory milestone regarding the company's lead product candidate, CardiAMP® Cell Therapy, intended for the treatment of ischemic heart failure.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statement data.
Material Changes and Regulatory Update
On April 20, 2026, Biocardia reported a positive outcome from a formal clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA). Key developments include:
- Regulatory Determination: The PMDA determined that clinical safety and efficacy evidence for CardiAMP® is likely sufficient to support market clearance in Japan.
- Data Acceptance: Good alignment was achieved regarding the acceptability of foreign clinical data developed in the United States.
- Strategic Alignment: The meeting confirmed agreement on indications for use, the approach for therapy introduction in Japan, and the necessity of continued post-marketing studies.
Outlook and Management Commentary
Management indicated that the company will await the official minutes from the PMDA to receive detailed feedback and a timeline for a potential regulatory filing. The press release attached as Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the official PMDA minutes for specific timelines and any conditions attached to the "likely sufficient" determination.
- Review the attached press release (Exhibit 99.1) for details on the scope of required post-marketing studies in Japan.
- Monitor subsequent filings for the formal submission date of the marketing application in Japan.
- Assess the impact of this regulatory progress on the company's cash burn rate and capital requirements, as no financial data is provided in this 8-K.